Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.38 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.38 |
| ▸ | PLK1 | P53350 | 2/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 10/20 | 0.36 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | THRA | P10827 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6026545 | 0.87 | HTR2A (0.41) | HTR2AHTR2CHTR2BPARP10PARP15 | |
| SCHEMBL6026202 | 0.86 | KMT2A (0.38) | — | |
| SCHEMBL6026363 | 0.81 | PTGS1 (0.35) | — | |
| SCHEMBL6025169 | 0.78 | EDNRA (0.47) | — | |
| SCHEMBL6021255 | 0.78 | STING1 (0.46) | PARP10PARP15PLK1TDP1DYRK1A | |
| SCHEMBL6021540 | 0.78 | STING1 (0.46) | PARP10PARP15PLK1TDP1DYRK1A | |
| SCHEMBL6026496 | 0.78 | PIK3CD (0.36) | — | |
| SCHEMBL6026223 | 0.78 | STING1 (0.47) | — | |
| SCHEMBL6020839 | 0.77 | STING1 (0.47) | PARP10PARP15PLK1TDP1DYRK1A | |
| SCHEMBL6021442 | 0.77 | STING1 (0.46) | HTR2APLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1664037-A1 | HALO SUBSTITUTED BENZO [B] THIOPHENES WITH PI3K INHIBITORY ACTIVITY AS THERAPEUTIC AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2006-06-07 | — | — | EP | disclosed |
| US-20050096350-A1 | Halo substituted benzo[b]thiophenes as therapeutic agents | CONNOLLY MICHAEL K (US) | 2005-05-05 | — | — | US | disclosed |
| WO-2005023800-A1 | HALO SUBSTITUTED BENZO`B! THIOPHENES WITH PI3K INHIBITORY ACTIVITY AS THERAPEUTIC AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2005-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096350-A1 | Halo substituted benzo[b]thiophenes as therapeutic agents | HCLS1, BRI3BP, BRPF1 | HTR2A 3429/4885HTR2C 2470/4885HTR2B 1442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.